Location: Home > Scientists
  Scientists
Name:
 Tuo Wei
Subject:
 Regenerative Medicine
Tel/Fax:
 +86-10-64808037  / 
E-mail:
 weituo@ioz.ac.cn
Address:
 State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, 1 Beichen West Road, Chaoyang District, Beijing 100101, P.R. China
More:
 Group of Nanotechnology based Drug Delivery      
Resume:

Biography:

Tuo Wei, Ph.D., Professor. Dr. Wei received her Ph.D. degree from the National Center for Nanoscience and Technology, University of Chinese Academy of Sciences, and Aix-Marseille University (France). She worked as a postdoctoral researcher at Harvard Medical School, Massachusetts Institute of Technology, and UT Southwestern Medical Center from 2015 to 2021. Then, in September 2021, she joined the State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, and led the Nanotechnology and Drug Delivery Research Group. The central goal of Dr. Wei’s lab is to develop safe and efficient nanocarriers for the treatment of cancer and genetic diseases. To date, she has published over 40 scientific papers in high-impact journals such as Nat Nanotechnol., Nat Commun. and Adv Mater. with more than 7000 total citations and an H-index of 33 (Google Scholar). She has 15 Chinese and international patent applications (9 of which have been granted).

Academic Appointments

Dr. Wei serves as the Young Editorial Board Member of the journal of “Exploration”, the Editorial Board Member of the “Journal of Functional Biomaterials”, the Young Editorial Board Member of the journal of “iLiver”, and is a member of the Nano-oncology Committee of the Chinese Anti-Cancer Association. In addition, she serves as an invited reviewer for Nano Today, Angewandte Chemie, Advanced Science, and other prestigious journals.

Research Interests:

Our research group focuses on the key scientific questions in the treatment of deadly human diseases (such as cancer, genetic diseases, etc.) and utilizes multidisciplinary technologies including chemistry, material science, biology, and medicine to design and develop novel nano-delivery technology platforms for highly efficient and targeted delivery of small molecule drugs and biomacromolecules (such as RNA, proteins, and gene editing systems), and to broaden and deepen their applications in the biomedical field.

The research fields include:

(1) Development of organ/cell type targeted delivery systems

(2) Development of novel delivery systems for gene editing and gene editing-based therapeutics;

(3) Targeted gene therapy for fatal human diseases (e.g., tumors, metabolic diseases, and genetic diseases).

Awards and Honors:

Professional Activities:

Research Grants:

Selected Publications:
  1. Luo Z, Lin Y, Meng Y, Li M, Ren H, Shi H, Cheng Q*, Wei T*. Spleen-Targeted mRNA Vaccine Doped with Manganese Adjuvant for Robust Anticancer Immunity In Vivo. ACS Nano. 2024, doi: 10.1021/acsnano.4c09902.
  2. Fei Y, Yu X, Liu P, Ren H, Wei T*, Cheng Q*. Simplified Lipid Nanoparticles for Tissue- And Cell-Targeted mRNA Delivery Facilitate Precision Tumor Therapy in a Lung Metastasis Mouse Model. Adv Mater. 2024, doi: 10.1002/adma.202409812.
  3. Lin Y, Cheng Q*, Wei T*. Surface Engineering of Lipid Nanoparticles: Targeted Nucleic Acid Delivery and Beyond. Biophys Rep. 2023, 9(5): 255-278. (Invited Review)
  4. Wei T#, Sun Y#, Cheng Q#, Chatterjee S, Traylor Z, Johnson LT, Coquelin ML, Wang J, Torres MJ, Lian X, Wang X, Xiao Y, Hodges CA, Siegwart DJ. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat Commun. 2023, 14(1):7322.
  5. Zong Y, Lin Y, Wei T*, Cheng Q*. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy. Adv Mater. 2023, https://doi.org/10.1002/adma.202303261.
  6. Wei T*, Tao W*, Cheng Q*. Lipid nanoparticles for mRNA therapy: recent advances in targeted delivery. Life Medicine. 2022, https://doi.org/10.1093/lifemedi/lnac004.
  7. Wei T#, Cheng Q#, Min YL, Olson EN, Siegwart DJ*. Systemic nanoparticle delivery of CRISPR/Cas9 ribonucleoproteins for effective tissue-specific genome editing. Nat Commun. 2020, 11(1):3232. (ESI高被引论文)
  8. Cheng Q#, Wei T#, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ*. Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing. Nat Nanotechnol. 2020, 15(4):313. (ESI高被引论文)
  9. Wei T, Cheng Q, Farbiak L, Anderson DG*, Langer R*, Siegwart DJ*. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for in Vivo CRISPR/Cas-Based Genome Editing. ACS Nano. 2020, 14(8):9243.(Invited Review)
  10. Liu J#, Wei T#, Zhao J, Huang Y, Deng H, Kumar A, Wang C, Liang Z, Ma X*, Liang X-J*. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance. Biomaterials. 2016, 91:44.
  11. Wei T, Chen C, Liu J, Liu C, Posocco P, Liu X, Cheng Q, Huo S, Liang Z, Fermeglia M, Pricl S, Liang X-J*, Rocchi P, Peng L*. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A. 2015, 112(10):2978.
  12. Wei T#, Liu J#, Ma H, Cheng Q, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang X-J*. Functionalized Nanoscale Micelles Improve Drug Delivery for Cancer Therapy in Vitro and in Vivo. Nano Lett. 2013, 13(6):2528.

（#Co-first author, *Corresponding author）